Key result
Electrophysiological profiling evaluates cardiac rhythm disturbances and cardiovascular involvement in acute leukemia patients.
Why the study?
Current guidelines classify arrhythmias as a distinct component of cancer therapy-related cardiovascular toxicity and emphasize the need for their proactive detection. This study aimed to characterize the electrophysiological profile of patients with acute leukemias and evaluate its role within the spectrum of cardiovascular involvement.
Observational
Answers are grounded in this paper and cite their sources.
No quantitative data guide rhythm management in acute leukemia; leaves open the utility of electrophysiological profiling.
Cardiac rhythm disturbances in patients with oncological or oncohematological diseases may stem not only from the direct cardiotoxicity of anticancer drugs but also from anemia, infectious or inflammatory complications, electrolyte imbalances, neurohumoral activation, and pre-existing cardiovascular disease. Current guidelines classify arrhythmias as a distinct component of cancer therapy-related cardiovascular toxicity and emphasize the need for their proactive detection. [1–4]. To characterize the electrophysiological profile of patients with acute leukemias and to evaluate its role within the complex spectrum of cardiovascular involvement, taking into account clinical symptoms, anemia, echocardiographic parameters, and cardiospecific biomarkers.
No takes yet. Share an insight, caveat, or question.
M.B. et al. (2026) conducted an observational in Acute leukemias. Acute leukemia and cancer therapy-related cardiovascular factors was evaluated on Electrophysiological profile and cardiac rhythm disturbances.
Synapse has enriched 10 related papers. Consider them for comparative context: